LINC00152 upregulates ZEB1 expression and enhances epithelial-mesenchymal transition and oxaliplatin resistance in esophageal cancer by interacting with EZH2
Authors:
Open Access
- 26 November 2020
- journal article
- research article
- Published by Springer Nature in Cancer Cell International
- Vol. 20 (1) , 1-14
Abstract
Background: Expression of the long non-coding mRNA LINC00152 has been reported to correlate with cancer cell resistance to oxaliplatin (L-OHP). However, little is known regarding the molecular mechanism of LINC00152 in esophageal cancer (EC). Hence, we intended to characterize the role of LINC00152 in EC, with a special focus on epithelial-mesenchymal transition (EMT) and L-OHP resistance. Methods: We collected EC tissues and identified EC cell lines with higher L-OHP resistance, and then characterized expression patterns of LINC00152, Zeste Homologue 2 (EZH2), Zinc finger e-box binding homeobox (ZEB1) and EMT-related genes using RT-qPCR and Western blot analysis. Furthermore, their functional significance was identified by gain and loss-of-function experiments. The relationship among LINC00152, EZH2 and ZEB1 was examined using RIP, RNA pull-down and ChIP assays. Additionally, resistance of EC cells to L-OHP was reflected by CCK-8 assay to detect cell viability. Animal experiments were also conducted to detect the effects of the LINC00152/EZH2/ZEB1 on EMT and L-OHP resistance. Results: LINC00152, EZH2 and ZEB1 were highly expressed in EC tissues and Kyse−150/TE-1 cells. As revealed by assays in vitro and in vivo, LINC00152 positively regulated ZEB1 expression through interaction with EZH2 to enhance EMT and L-OHP resistance in EC cells. In contrast, silencing of LINC00152 contributed to attenuated EMT and drug resistance of EC cells to L-OHP. Conclusions: Our study demonstrates that LINC00152/EZH2/ZEB1 axis can regulate EMT and resistance of EC cells to L-OHP, thus presenting a potential therapeutic target for EC treatment.Keywords
Funding Information
- Third Batch and Fourth Batch of Medical and Health Science and Technology Program Project Funds in Shantou City in 2018 (Shan Fu Ke letter (2018) 238)
- Dedicated Fund for Tumor-Targeting of Wu Jieping Medical Fundation supported (Project ID: 320.6750.19090-32)
This publication has 46 references indexed in Scilit:
- Upregulation of long noncoding RNA SPRY4-IT1 promotes metastasis of esophageal squamous cell carcinoma via induction of epithelial–mesenchymal transitionCell Biology and Toxicology, 2016
- ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer typesNature Communications, 2016
- The Clinical Relevance of Long Non-Coding RNAs in CancerCancers, 2015
- EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approachesJournal of Experimental & Clinical Cancer Research, 2015
- Randomized Phase 2 Trial of S1 and Oxaliplatin-Based Chemoradiotherapy With or Without Induction Chemotherapy for Esophageal CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Increased Levels of the Long Intergenic Non–Protein Coding RNA POU3F3 Promote DNA Methylation in Esophageal Squamous Cell Carcinoma CellsGastroenterology, 2014
- Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significanceTumor Biology, 2014
- Epidemiology of esophageal cancerWorld Journal of Gastroenterology, 2013
- High expression of ZEB1 correlates with liver metastasis and poor prognosis in colorectal cancerOncology Letters, 2012
- High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapyInternational Journal of Cancer, 2010